4//SEC Filing
INKINE PHARMACEUTICAL CO INC 4
Accession 0001125282-05-005149
CIK 0000929547operating
Filed
Oct 3, 8:00 PM ET
Accepted
Oct 4, 5:49 PM ET
Size
14.0 KB
Accession
0001125282-05-005149
Insider Transaction Report
Form 4
SCHELLENGER NORMAN D
Director
Transactions
- Disposition to Issuer
Common Stock (right to buy)
2005-09-30−5,000→ 0 totalExercise: $3.92Exp: 2014-08-22→ Common Stock (5,000 underlying) - Disposition to Issuer
Common Stock (right to buy)
2005-09-30−30,500→ 0 totalExercise: $2.82Exp: 2013-06-01→ Common Stock (30,500 underlying) - Disposition to Issuer
Common Stock (right to buy)
2005-09-30−21,000→ 0 totalExercise: $4.20Exp: 2014-06-06→ Common Stock (21,000 underlying) - Disposition to Issuer
Common Stock (right to buy)
2005-09-30−51,000→ 0 totalExercise: $2.11Exp: 2015-06-07→ Common Stock (51,000 underlying) - Disposition to Issuer
Common Stock (right to buy)
2005-09-30−25,000→ 0 totalExercise: $1.60Exp: 2012-11-10→ Common Stock (25,000 underlying)
Footnotes (1)
- [F1]All of the options described above were converted in the merger into options to purchase Salix common stock based on an exchange ratio of 0.1737. These options, which are fully vested, now represent the right to purchase 23,015 shares of Salix common stock at a weighted average exercise price of $14.89 per share.
Documents
Issuer
INKINE PHARMACEUTICAL CO INC
CIK 0000929547
Entity typeoperating
IncorporatedNY
Related Parties
1- filerCIK 0000929547
Filing Metadata
- Form type
- 4
- Filed
- Oct 3, 8:00 PM ET
- Accepted
- Oct 4, 5:49 PM ET
- Size
- 14.0 KB